UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Unmet needs in the first-line treatment of follicular lymphoma

Annals of oncology, 2017-09, Vol.28 (9), p.2094-2106

2017

Link zum Volltext

Verfügbarkeit prüfen

Acute and Late Toxicity of Bilateral Orbital Irradiation in the Management of Primary Intraocular Lymphoma

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E490-E490

2016

Link zum Volltext

Verfügbarkeit prüfen

Radiation Therapy Improves Outcomes in Patients With Primary Testicular Diffuse Large B-cell Lymphoma

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S20-S20

2016

Link zum Volltext

Verfügbarkeit prüfen

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Annals of oncology, 2015-06, Vol.26 (6), p.1175-1179

2015

Link zum Volltext

Verfügbarkeit prüfen

Breakthrough therapies in B-cell non-Hodgkin lymphoma

Annals of oncology, 2016-05, Vol.27 (5), p.778-787

2016

Link zum Volltext

Verfügbarkeit prüfen

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.182-183

2019

Link zum Volltext

Verfügbarkeit prüfen

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Annals of oncology, 2016-05, Vol.27 (5), p.895-901

2016

Link zum Volltext

Verfügbarkeit prüfen

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Annals of oncology, 2016-07, Vol.27 (7), p.1317-1323

2016

Link zum Volltext

Verfügbarkeit prüfen

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

Hematological oncology, 2019-06, Vol.37 (S2), p.227-229

2019

Link zum Volltext

Verfügbarkeit prüfen

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.182-183

2019

Link zum Volltext

Verfügbarkeit prüfen

HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO

Hematological oncology, 2019-06, Vol.37 (S2), p.232-234

2019

Link zum Volltext

Verfügbarkeit prüfen

THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY

Hematological oncology, 2017-06, Vol.35 (S2), p.268-269

2017

Link zum Volltext

Verfügbarkeit prüfen

PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

HemaSphere, 2019-06, Vol.3 (S1), p.571-572

2019

Link zum Volltext

Verfügbarkeit prüfen

PF483 EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY

HemaSphere, 2019-06, Vol.3, p.193-194

2019

Link zum Volltext

Verfügbarkeit prüfen

COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.266-267

2017

Link zum Volltext

Verfügbarkeit prüfen

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

Hematological oncology, 2017-06, Vol.35 (S2), p.112-113

2017

Link zum Volltext

Verfügbarkeit prüfen

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

HemaSphere, 2019-06, Vol.3 (S1), p.577-578

2019

Link zum Volltext

Verfügbarkeit prüfen

The agronomic and economic potential of break crops for ley/arable rotations in temperate organic agriculture

Advances in Agronomy, 2002, Vol.77, p.369-427

2002

Link zum Volltext

Verfügbarkeit prüfen

P-374

Fertility and sterility, 2006-09, Vol.86 (3), p.S274

2006

Link zum Volltext

Verfügbarkeit prüfen

P-374: Herbal therapy for endometriosis: Prunella vulgaris (self heal) reduces the size and number endometriotic xenografts in immunodeficient RAG-2/gamma(c) knockout mice

Fertility and sterility, 2006, Vol.86 (3), p.S274-S274

2006

Link zum Volltext

Verfügbarkeit prüfen

Tarp Filtering of Block-Transform Coefficients for Embedded Image Coding

2006 IEEE International Conference on Acoustics Speech and Signal Processing Proceedings, 2006, Vol.2, p.II-II

2006

Link zum Volltext
IEEE_Xplore

Organic dairy production: a review

Biological agriculture & horticulture, 2004, Vol.22 (3), p.217-249

2004

Link zum Volltext

Verfügbarkeit prüfen

Effects of a partially hydrolyzed guar gum on intestinal absorption of carbohydrate, protein and fat: a double-blind controlled study in volunteers

Clinical nutrition (Edinburgh, Scotland), 1998-06, Vol.17 (3), p.125-129

1998

Link zum Volltext

Verfügbarkeit prüfen

JPEG2000 coding strategies for hyperspectral data

Proceedings. 2005 IEEE International Geoscience and Remote Sensing Symposium, 2005. IGARSS '05, 2005, Vol.1, p.4 pp.

2005

Link zum Volltext
IEEE_Xplore

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(30)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(9)
Humans
(8)
Adult
(6)
Middle Aged
(6)
Monoclonal Antibodies
(6)
Immunotherapy
(5)
Male
(5)
Oncology
(5)
Targeted Cancer Therapy
(5)
Aged
(4)
Aged, 80 And Over
(4)
Disease-Free Survival
(4)
Female
(4)
Lymphoma
(4)
Rituximab
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Image Coding
(3)
Patients
(3)
Treatment
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Unmet needs in the first-line treatment of follicular lymphoma

Acute and Late Toxicity of Bilateral Orbital Irradiation in the Management of Primary Intraocular Lymphoma

Radiation Therapy Improves Outcomes in Patients With Primary Testicular Diffuse Large B-cell Lymphoma

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Breakthrough therapies in B-cell non-Hodgkin lymphoma

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO

THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY

PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

PF483 EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY

COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

The agronomic and economic potential of break crops for ley/arable rotations in temperate organic agriculture

P-374

P-374: Herbal therapy for endometriosis: Prunella vulgaris (self heal) reduces the size and number endometriotic xenografts in immunodeficient RAG-2/gamma(c) knockout mice

Tarp Filtering of Block-Transform Coefficients for Embedded Image Coding

Organic dairy production: a review

Effects of a partially hydrolyzed guar gum on intestinal absorption of carbohydrate, protein and fat: a double-blind controlled study in volunteers

JPEG2000 coding strategies for hyperspectral data

Suchergebnisse filtern